Tijaabo Caafimaad oo Cusub oo Bukaannada qaba COVID-19 oofwareen Halis ah

Written by editor

CalciMedica Inc., CRAC (kaalshiyamka calcium-ka-shaqeeya ee kaalshiyamka ah) ee shirkadda kanaalka, ayaa maanta ku dhawaaqday bilawga CARDEA-Plus, tijaabo caafimaad oo Waji 2b ah oo lagu qabanayo Maraykanka iyo Kanada, taas oo u adeegi karta hogaaminta Wajigeeda 3 barnaamijka horumarinta ee Auxora™ ee bukaanada qaba COVID-19 oof wareenka daran.

Print Friendly, PDF & Email

Tijaabada waxaa loogu talagalay in lagu ururiyo xogta badbaadada bukaanka dheeraadka ah ee Auxora, qiimaynta badbaadada iyo waxtarka Auxora oo ay weheliso tocilizumab iyo corticosteroids labadaba, iyo in la qiimeeyo badbaadada iyo waxtarka saddex iyo lixda maalmood ee qaadashada. Shirkadda ayaa dhawaan ka warbixisay xogta ugu sareysa ee laga helay tijaabadeeda Wajiga 2 ee CARDEA taasoo taageerta daraasado dheeraad ah oo lagu sameeyay dadka bukaanka ah. 

CARDEA-Plus waxay diiwaangelin doontaa bukaannada COVID-19 oof wareenka oo leh saamiga PaO2/FiO2 (P/F) ee ≤200 kuwaas oo u baahan marin-socodka sanka ee qulqulaya (HFNC) ama hawo-qaadasho aan fiicneyn (NIV). Bukaan-socodka ayaa heli doona 2.0 mg/kg qiyaasta hore ee Auxora oo ay ku xigto 1.6 mg/kg saacadaha 24, iyo 1.6 mg/kg saacadaha 48. Bukaannada qaba saamiga P/F ee ≤100 ama hawo farsamo 48 saacadood waxay xaq u yeelan doonaan in la kala sooco si ay u helaan mid ka mid ah saddex qiyaasood oo Auxora ah ama saddex qiyaasood oo placebo ah. Dhammaan bukaannada ayaa heli doona heerka daryeelka taasoo ay ku jiri karto isticmaalka corticosteroids iyo/ama tocilizumab.

"In kasta oo ay sii kordhayaan heerarka tallaalka ee COVID-19, tirada badan ee isbitaallada la seexinayo iyo dhimashada ayaa weli ah dhibaato weyn," ayuu yiri Sudarshan Hebbar, MD, Madaxa Caafimaadka ee CalciMedica. "Iyadoo tocilizumab si weyn loogu isticmaalo bukaannada isbitaalada la dhigo COVID-19, waxaa sii socota baahida loo qabo hagaajinta natiijooyinka bukaanka. Waxaan aaminsanahay in Auxora ay leedahay hannaan ficil oo gaar ah iyo guryaha farmashiyaha oo laga yaabo inay faa'iido caafimaad siiyaan bukaannada qaba COVID-19 oof wareenka halista ah."

"Bilawga daraasaddan, oo sidoo kale u oggolaanaysa maamulka Auxora oo leh tocilizumab iyo corticosteroids ee bukaannada qaba COVID-19 oof wareenka halista ah, ayaa guul muhiim ah u ah Shirkaddayada," ayuu yiri Rachel Leheny, Ph.D., Madaxa Fulinta ee CalciMedica. . " Muhiimad ahaan, natiijooyinka daraasaddan, oo ay ku xigto wadahadal lala yeesho FDA, waxay ku wargelin doontaa naqshadeynta tijaabada bukaan-socodka ee Wajiga 3 ee suurtogalka ah dabayaaqada sanadkan. Waxa aanu xamaasad ballaadhan iyo taageero ka helnay goobaha baadhayaashu daraasaddan oo aanu filayno is-diiwaangelin degdeg ah.”

Print Friendly, PDF & Email

War ku saabsan qoraaga

editor

Tifaftiraha madaxa eTurboNew waa Linda Hohnholz. Waxay ku salaysan tahay eTN HQ ee Honolulu, Hawaii.

Leave a Comment